|
Abbott Hits Watson With Second Suit Against Expanded Niaspan ANDA
Abbott is continuing to put legal pressure on Watson now that the generic-drug maker has expanded its Niaspan ANDA to include the 750-mg version of Abbott’s billion-dollar cholesterol treatment.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives